Novel Topical Treatment for Postherpetic Neuralgia

带状疱疹后神经痛的新型局部治疗

• 批准号: 6991051
• 负责人: Charles J Gauntt
• 金额: $ 19.69万
• 依托单位: BIOMEDICAL DEVELOPMENT CORPORATION
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6991051
• 关键词: analgesia; chemotherapy; chronic pain; clinical research; clinical trials; drug delivery systems; drug design /synthesis /production; drug screening /evaluation; human subject; human therapy evaluation; local anesthetics; patient oriented research; polymers; shingles; slow release drug; topical drug application

DESCRIPTION (provided by applicant): The goal of this project is to develop a novel topical drug delivery vehicle to treat postherpetic neuralgia [PHN). PHN is defined as pain in the affected dermatome that persists or appears after the rash of herpes zoster (HZ) has healed. Although many cases of PHN resolve over time, for many patients the pain is chronic, causing a devastating impact on quality of life. Systemic treatments for PHN are associated with undesirable adverse effects, which can be particularly problematic for elderly patients. Topical treatments such as capsaicin cream, acetylsalicylic acid (aspirin), anesthetic creams, and lidocaine patches either require multiple daily applications or are limited in their use due to the potential for elevated systemic absorption of the topical compound. In previous work, Biomedical Development Corporation (BDC) has developed a novel polymer-based coating composition that is useful for several biomedical applications. The coating is capable of sustained topical drug delivery. The objective of this project is to use these coatings as a treatment for the pain associated with postherpetic neuralgia. The Specific Aims of the grant are as follows: Specific Aim 1: Formulate Coatings for the Treatment of Postherpetic Neuralgia Specific Aim 2: Demonstrate Efficacy of Coatings in a Human Clinical Trial Relevance to Public Health: Herpes zoster (shingles) is one of the most common neurologic diseases in the U.S. Although there have been no systematic attempts to investigate the prevalence of post herpetic neuralgia, estimates have ranged from 500,000 to 1 million in the U.S. The incidence of PHN among those with herpes zoster ranges from 10 to 70 percent and increases with advancing age and the intractability of the pain may also increase with age. The incidence of herpes zoster, and therefore the incidence of PHN, is predicted to increase in the coming decades because of both the aging population and as a consequence of childhood varicella vaccination. The ongoing spontaneous pain and particularly the allodynic component of PHN can be debilitating and can lead to co-morbid conditions such as depression, social isolation, anxiety and sleep disturbance, as well as increased health care utilization.

描述(申请人提供)：该项目的目标是开发一种新的局部药物输送载体来治疗带状疱疹后神经痛[PHN]。PHN被定义为在带状疱疹(HZ)皮疹痊愈后持续或出现在受影响皮肤处的疼痛。虽然许多PHN病例会随着时间的推移而消失，但对许多患者来说，疼痛是慢性的，对生活质量造成毁灭性的影响。对PHN的系统治疗与不良反应有关，这对老年患者来说可能特别成问题。局部治疗，如辣椒素乳膏、乙酰水杨酸(阿司匹林)、麻醉剂乳膏和利多卡因贴片，要么需要每天多次使用，要么由于局部化合物的潜在全身吸收增加而受到限制。 在之前的工作中，生物医学开发公司(BDC)开发了一种新型的聚合物基涂层组合物，该组合物可用于多种生物医学应用。该涂层能够持续的局部给药。该项目的目标是使用这些涂层作为治疗与带状疱疹后神经痛相关的疼痛。这笔赠款的具体目的如下：具体目标1：配制治疗带状疱疹后神经痛的涂料特殊目标2：在一项与公共卫生相关的人类临床试验中证明涂料的有效性：带状疱疹(带状疱疹)是美国最常见的神经系统疾病之一。虽然还没有系统的尝试来调查带状疱疹后神经痛的患病率，但在美国估计从50万到100万不等。带状疱疹患者的PHN发病率从10%到70%，并随着年龄的增加而增加，疼痛的顽固性也可能随着年龄的增加而增加。由于人口老龄化和儿童接种水痘疫苗的结果，带状疱疹的发病率以及因此PHN的发病率预计在未来几十年将增加。持续的自发性疼痛，特别是PHN的痛觉异常成分，可能会使人虚弱，并可能导致抑郁、社交孤立、焦虑和睡眠障碍等共病情况，以及增加卫生保健利用率。